

## SP0050

### Treatment recommendations and predictors in Eating Disorders

F. Fernandez-Aranda<sup>1,2,3\*</sup>

Eating Disorders Section and Eating Disorders Section

<sup>1</sup>Clinical Psychology, University Hospital of Bellvitge-IDIBELL;

<sup>2</sup>CIBERobn, ISCIII and <sup>3</sup>Clinical Sciences, University of Barcelona, Barcelona, Spain

\*Corresponding author.

doi: 10.1192/j.eurpsy.2024.97

**Abstract:** Eating disorders are severe mental disorders with a high mortality rate - suicidality - and a high incidence in adolescence and early adulthood, especially in women. The course of these disorders is uncertain and treatment outcomes are limited, with successful outcomes in 50-75% of cases. For bulimia nervosa (BN) and binge eating disorder (BED), several factors, such as duration of the disorder, eating and general psychopathology, dysfunctional personality traits and cognitive impairment, have been found to be associated with treatment adherence and response. In anorexia nervosa (AN) and atypical ED (OSFED), treatment response is poorer, with higher dropout rates and longer duration and chronicity. In this presentation, we will describe recent prospective observational studies in large samples of EDs analysing clinical, personality and cognitive predictors of treatment response in eating disorders, as well as potential associated neurobiomarkers. Optimisation of health care resources and transitions, as well as early and effective personalised treatments, can change the trajectory of EDs.

**Disclosure of Interest:** F. Fernandez-Aranda Grant / Research support from: We thank CERCA Programme/Generalitat de Catalunya for institutional support. We also want to thank the Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) and ISCIII (CIBERobn is its initiative). This research was supported by grants from Instituto de Salud Carlos III (ISCIII) (FIS PI20/00132) and co-funded by FEDER funds/European Regional Development Fund (ERDF), a way to build Europe. Additional support was received from the Delegación del Gobierno para el Plan Nacional sobre Drogas (2021I031) and Ministerio de Ciencia e Innovación (grant PID2021-124887OB-I00), but also AGAUR-Generalitat de Catalunya (2021-SGR-00824), European Union's Horizon 2020 research and innovation program under Grant agreement no. 847879 (PRIME/H2020, Prevention and Remediation of Insulin Multimorbidity in Europe) and the European Union's Horizon Europe research and innovation program under grant agreement No 101080219 (eprObes), Consultant of: FFA received consultancy and speakers honoraria from Novo Nordisk.

## SP0051

### Treatment strategies in eating disorders with comorbid conditions and in under-represented clinical populations

G. Paslakis

University Clinic for Psychosomatic Medicine and Psychotherapy, Ruhr-University Bochum, Campus East-Westphalia, Luebbecke, Germany

doi: 10.1192/j.eurpsy.2024.98

**Abstract:** Eating disorders (EDs) have long been thought to be conditions that only or mainly affect women, especially young, affluent, skinny girls and women in Western cultures. Mostly over the last decade, we have come to realize that EDs may affect individuals of all genders, ages, sexual orientations, ethnic, and socio-economic backgrounds. This, in turn, has implications for ED presentation and assessment, and the necessity for adjustments in the provided care according to diverse treatment needs. Here, we present and discuss current advances in ED-related research in underrepresented groups as well as the need to further incorporate diversity aspects in clinical care and research within the ED realm.

**Disclosure of Interest:** None Declared

## SP0052

### Reconceptualising depression along the endogenous-reactive spectrum: are different genes involved in depression depending on presence vs absence of exposure to stress?

X. Gonda

Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary

doi: 10.1192/j.eurpsy.2024.99

**Abstract:** Depression is a complex and highly heterogeneous disorder with an omnigenic and multifactorial background. This diversity is obvious not only in its symptomatic manifestation but also in its neurobiological underpinnings which is one potential factor contributing to the high observed rate of treatment resistance. Thus, subtyping depressions, understanding their distinct neurobiological and genetic background, and potentially developing biomarkers aiding their differential diagnosis may bring us one step closer to more effective treatment. The present talk will overview the different etiological factors contributing to the emergence of depression along an endogenous-reactive continuum, the contributory roles of different types of stress, different genes involved in distinct processes, and the potential consequences of conceptualising, diagnosing and treating depressions developing in the context or independently of current stress.

**Disclosure of Interest:** None Declared

## SP0053

### Is bipolar mixed depression associated with a good response to psychotropic augmentation?

Z. Rihmer

Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary

doi: 10.1192/j.eurpsy.2024.100

**Abstract:** Is bipolar mixed depression associated with a good response to psychotropic augmentation? Zoltán Rihmer Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest